Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.
about
Application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part I. Diagnosis of breast cancer prior to treatmentThe Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer.Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer.Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancerDefining the role of PET-CT in staging early breast cancer.Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.Clinical impact of (18)F-FDG PET/CT on initial staging and therapy planning for breast cancer.Bone scan or (18)f-fluorodeoxyglucose positron emission tomography/computed tomography; which modality better shows bone metastases of breast cancer?Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in the Initial Staging and Response Assessment of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Chemotherapy(18)F-FDG/PET May Help to Identify a Subgroup of Patients with T1-T2 Breast Cancer and 1-3 Positive Lymph Nodes Who Are at a High Risk of Recurrence after MastectomyQuantitative Evaluation of Therapeutic Response by FDG-PET-CT in Metastatic Breast CancerDisease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.Special Relevance of FDG-PET as an Upfront Diagnostic Modality at Initial Diagnosis and in Suspected Recurrence in Patients of Breast Carcinoma Hailing From Lower Socioeconomic Status Owing to Relative Late Presentation: A Pilot Study in a Medical CClinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer.The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT.Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.Present and future role of FDG-PET/CT imaging in the management of breast cancer.Robot-assisted internal mammary lymph chain excision for breast cancer: A case reportFDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: A pilot study.Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT.18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.Should FDG PET/CT be used for the initial staging of breast cancer?Whole-body 18FDG-PET/CT or whole-body gadolinium-enhanced MRI for distant staging?Use of imaging for staging of early-stage breast cancer in two integrated health care systems: adherence with a choosing wisely recommendation.Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging.Detection of distant metastases in patients with locally advanced breast cancer: role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging with computed tomography scans.Comparisons of Positron Emission Tomography/Computed Tomography and Ultrasound Imaging for Detection of Internal Mammary Lymph Node Metastases in Patients With Breast Cancer and Pathologic Correlation by Ultrasound-Guided Biopsy Procedures.(18) F-FDG PET/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer.Preoperative PET/CT in early-stage breast cancer.Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact
P2860
Q26751999-D92F84F6-2931-4B9B-90C6-8F541388C43FQ34097237-CB71829B-E6C7-4FD6-BD78-2B88874C4C00Q35552138-7C7D10A4-7D1F-4790-BB72-A87450CCB5CEQ35584721-C4AEE94B-4764-44AF-8F62-EFF83C1EEEDAQ35584948-B14E8DC4-880B-4831-AD4A-5D6D5A2EE118Q35989958-E82A1FE4-3AC4-4461-AB09-9153129F8DFEQ36109265-131482E3-2444-43F8-9615-1E159A6726A2Q36409205-BAF9B79B-6DD5-4559-B5F4-9EA6FE0DC7A4Q36457878-7F28DB3E-4E98-4267-A054-42BE0C75FEE4Q36476568-96352364-0397-4F69-9ABC-FAA39C224D25Q36734702-2A4BB63A-5B1E-4184-878B-1C86CDC0B197Q36832255-71D1E5FC-AFE0-4072-8A6A-5CE15D4B7A00Q36883389-F2F383E5-916D-44D3-8674-9BB7A75B8786Q37477631-EF0E956E-C6B8-4A42-94DA-23FED6B7141AQ37660339-ACD02045-6517-44C4-B22B-E74BF9A2A76FQ38165388-A31CE6B7-078D-4D5C-8335-FA41E43B7E1EQ38411448-3ABE7815-B400-4127-BF4C-31211C21F43CQ38445089-5BC42DB9-227C-4F8D-B343-702FD25EED0DQ38687620-F9E73581-7937-459C-A4F2-6FDD45447715Q41622013-913D2E67-AC16-4E17-8ABC-0AEDBD09496DQ43217467-E02C10B6-E1FD-4B90-A4BE-11A013581DB6Q44459789-9F046249-37A8-449B-A3E2-9FAC703F1FD5Q45915234-0F080DFD-4143-4438-9D2D-A213E256C29AQ46008082-B3309EF4-CF97-4248-9B47-8C8E267414EBQ46014390-6AFC6A09-49B0-4562-AEC4-7A08C5816E54Q46114763-8D6D9443-3072-4F3B-A89D-56F04101311FQ48118323-1075A820-B959-4382-AA48-57C77D00C9AAQ50145287-A0D14F69-0D6B-449F-B4F8-7BFFFCDD533AQ50877812-A2E06CBA-32EC-4E0B-B1CD-0AE4E2B1ABF3Q50959115-A0942A49-B9C4-4491-9E5C-263E4D7B2A19Q51408712-BF4ECF66-85F6-457F-B4FC-79A5EFAC8012Q53076367-C228A897-366D-4F4E-B56A-6F558D3FA81DQ53089607-2C9265A5-ACAD-422D-ADCB-914C2A4785F5Q53165455-19B3F3B7-AA50-4360-8DBB-7C6D43F16E95Q53174047-86FA5889-94FF-47F2-9599-18F39CBF44A3Q54336130-C2A2AA76-712C-4543-A3DD-0112CCF97A79Q57728676-FF30F77D-1349-4A16-8D2A-6E9A1C1133D6
P2860
Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Effect of (18)F-FDG PET/CT ima ...... tage II and III breast cancer.
@en
type
label
Effect of (18)F-FDG PET/CT ima ...... tage II and III breast cancer.
@en
prefLabel
Effect of (18)F-FDG PET/CT ima ...... tage II and III breast cancer.
@en
P2093
P1476
Effect of (18)F-FDG PET/CT ima ...... tage II and III breast cancer.
@en
P2093
Caroline Cuvier
Christophe Hennequin
David Groheux
Elif Hindie
Farid Sarandi
Georges Baillet
Jacques-Robert Vilcoq
Jean-Emmanuel Filmont
Jean-Louis Misset
Jean-Luc Moretti
P304
P356
10.1016/J.IJROBP.2008.02.056
P407
P577
2008-04-23T00:00:00Z